×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia
Yahoo Movies UK
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval.
2 days ago
FibroGen, Kind Pharma settle trade secrets theft dispute
Fierce Pharma
FibroGen originally sued Liu and Deng in December 2022 for allegedly pinching proprietary information and filing improper patents around hypoxia...
1 month ago
Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains (FGEN)
Seeking Alpha
FibroGen focuses on developing Pamrevlumab for pancreatic cancer therapy after disappointing trial results for other indications.
5 days ago
AstraZeneca Returns to FibroGen the Rights to Roxadustat in US, Other Territories
BioSpace
AstraZeneca Returns to FibroGen the Rights to Roxadustat in US, Other Territories ... AstraZeneca on Monday shut down the bulk of its roxadustat...
3 months ago
FibroGen's $28.5M Deal With 30K Investors Nears Tentative OK
Law360
A California federal judge indicated Wednesday that he'll preliminarily sign off on a $28.5 million settlement secured for a class of...
4 months ago
FibroGen to Participate in Upcoming Investor Conferences
GlobeNewswire
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company's management will participate...
4 weeks ago
In re FibroGen Inc. Securities Litigation
Cornerstone Research
Defense counsel retained Paul Zurek of Cornerstone Research as an expert witness. Dr. Zurek filed a class certification report in which he opined that the...
3 months ago
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
Yahoo Movies UK
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
2 days ago
FibroGen stock slips after data for prostate cancer drug
Seeking Alpha
FibroGen (FGEN) stock plunged after disappointing initial results from a Phase 1 study for its prostate cancer therapy. Read more here.
1 month ago
FibroGen to Report First Quarter 2024 Financial Results
Yahoo Finance
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday...
1 month ago